BDR Pharma has signed a license agreement with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the Defence Research and Development Organisation (DRDO) for the ...
The first batch of DRDO-developed anti-COVID drug 2-DG (2-deoxy-D-glucose) has been launched to treat patients suffering from the deadly COVID-19. The medicine comes in powder form and can be taken with water.